Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study

Jun Hakamata, Masayuki Hashiguchi, Yuko Kaneko, Kunihiro Yamaoka, Mikiko Shimizu, Junya Maruyama, Tsutomu Takeuchi, Mayumi Mochizuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2017 Dec 27

Fingerprint

Methotrexate
Rheumatoid Arthritis
Cohort Studies
Liver
Enzymes
Therapeutics
Glomerular Filtration Rate
Logistic Models
Electronic Health Records
Genetic Polymorphisms
Single Nucleotide Polymorphism
Real-Time Polymerase Chain Reaction
Reference Values
Outpatients
Multivariate Analysis
Observation
Safety

Keywords

  • Abnormal hepatic enzyme elevation
  • allele frequency
  • cohort study
  • methotrexate
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis : A hospital based-cohort study. / Hakamata, Jun; Hashiguchi, Masayuki; Kaneko, Yuko; Yamaoka, Kunihiro; Shimizu, Mikiko; Maruyama, Junya; Takeuchi, Tsutomu; Mochizuki, Mayumi.

In: Modern Rheumatology, 27.12.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{ff5b1b57ccaa431d843a6981dc0ca5a3,
title = "Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study",
abstract = "Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.",
keywords = "Abnormal hepatic enzyme elevation, allele frequency, cohort study, methotrexate, rheumatoid arthritis",
author = "Jun Hakamata and Masayuki Hashiguchi and Yuko Kaneko and Kunihiro Yamaoka and Mikiko Shimizu and Junya Maruyama and Tsutomu Takeuchi and Mayumi Mochizuki",
year = "2017",
month = "12",
day = "27",
doi = "10.1080/14397595.2017.1414765",
language = "English",
pages = "1--10",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis

T2 - A hospital based-cohort study

AU - Hakamata, Jun

AU - Hashiguchi, Masayuki

AU - Kaneko, Yuko

AU - Yamaoka, Kunihiro

AU - Shimizu, Mikiko

AU - Maruyama, Junya

AU - Takeuchi, Tsutomu

AU - Mochizuki, Mayumi

PY - 2017/12/27

Y1 - 2017/12/27

N2 - Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.

AB - Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.

KW - Abnormal hepatic enzyme elevation

KW - allele frequency

KW - cohort study

KW - methotrexate

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85039865345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039865345&partnerID=8YFLogxK

U2 - 10.1080/14397595.2017.1414765

DO - 10.1080/14397595.2017.1414765

M3 - Article

C2 - 29252093

AN - SCOPUS:85039865345

SP - 1

EP - 10

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -